

## Enhancement of internal ribosome entry site-mediated translation and replication of hepatitis C virus by PD98059

Takayuki Murata, Makoto Hijikata, Kunitada Shimotohno\*

*Department of Viral Oncology, Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan*

Received 13 April 2005; returned to author for revision 11 May 2005; accepted 8 June 2005

Available online 11 July 2005

### Abstract

Translation initiation of hepatitis C virus (HCV) occurs in an internal ribosome entry site (IRES)-dependent manner. We found that HCV IRES-dependent protein synthesis is enhanced by PD98059, an inhibitor of the extracellular signal-regulated kinase (ERK) signaling pathway, while cellular cap-dependent translation was relatively unaffected by the compound. Treatment of cells with PD98059 allowed for robust HCV replication following cellular incubation with HCV-positive serum. Though the molecular mechanism underlying IRES enhancement remains elusive, PD98059 is a potent accelerator of HCV RNA replication.

© 2005 Elsevier Inc. All rights reserved.

*Keywords:* HCV; IRES; ERK; Replication

### Introduction

Hepatitis C virus (HCV), a member of the family Flaviviridae, is an enveloped virus with a positive-, single-stranded, 9.6-kb RNA genome (Murphy et al., 1995). The virus is the major causative agent of non-A, non-B hepatitis (Choo et al., 1989) and an estimated 170 million people throughout the world are persistently infected. Although acute phase HCV infection, in most cases, is asymptomatic, the virus frequently establishes a persistent infection, which is associated with serious clinical diseases such as chronic hepatitis followed by liver cirrhosis and hepatocellular carcinoma (Goodman and Ishak, 1995).

Like other positive-stranded RNA viruses, the 5'-untranslated region (UTR) of HCV RNA genome functions as an internal ribosomal entry site (IRES) and mediates translation initiation in a cap-independent manner (Tsukiyama-Kohara et al., 1992). Nearly the entire 5'-UTR (340 nt) and a short sequence of the coding region downstream of the initiator AUG codon of the HCV genome serve as an IRES (Honda

et al., 1996). Unlike encephalomyocarditis virus (EMCV) or poliovirus, the 5' end of the HCV genome is modified by neither cap structure nor VpG but bears a phosphate residue (Takahashi et al., 2005).

Molecular biological investigations of HCV have been hampered for a long time because of the lack of cell culture system that efficiently supports HCV replication. However, establishment of an HCV subgenomic replicon cell culture system in 1999 (Lohmann et al., 1999) allowed for such studies to be undertaken. The subgenomic replicon RNA is composed of, in this order, the HCV 5'-UTR containing an IRES, neomycin phosphate transferase or luciferase gene, HCV nonstructural (NS) proteins 3 through 5B directed by an EMCV IRES and the HCV 3'-UTR. As the replicon RNA replicates autonomously in cultured cells, the system provides a unique tool to analyze the molecular mechanisms governing viral genome replication and protein synthesis. Additionally, this system facilitates the screening of anti-HCV compounds.

PD98059 was identified as a potent inhibitor of mitogenic-extracellular signal-regulated kinase (MEK)–extracellular signal-regulated kinase (ERK) signaling pathway and has been widely used as a specific inhibitor of the pathway. The MEK–ERK pathway is elicited by broad

\* Corresponding author. Fax: +81 75 751 3998.

E-mail address: [kshimoto@virus.kyoto-u.ac.jp](mailto:kshimoto@virus.kyoto-u.ac.jp) (K. Shimotohno).

range of growth factors or hormones and plays a crucial role in various events including cell growth promotion, differentiation, cell death and morphogenesis in eukaryotic cells (reviewed in Robinson and Cobb, 1997).

In this study, we demonstrate that PD98059 enhances HCV IRES-dependent translation. Because several lines of evidence suggest that IRES-mediated translation regulates replication in cultured cells (Lerat et al., 2000; He et al., 2003) and in vivo (Lott et al., 2001; Laporte et al., 2003; Forton et al., 2004), we examined the effect of PD98059 on viral replication. Although the RNA levels in replicon cells were relatively unaffected, PD98059 increased viral RNA levels in cultured cells infected with HCV-positive serum. Our results provide insight into the mechanisms of HCV IRES-dependent translation initiation and, in addition, suggest a simple infection system in cultured cells that supports HCV replication very efficiently.

## Results

### *Enhancement of luciferase-replicon or HCV IRES by PD98059*

We previously developed a highly efficient subgenomic HCV replicon system (Murata et al., 2005). Briefly, we used cured cells (curedMH14) as a host cell line, and the adaptive mutations were introduced into the subgenomic replicon construct for efficient replication. The luciferase gene was then placed under the control of the HCV IRES for rapid, quantitative and sensitive detection (Fig. 1, LMH14RNA). We have used this system to screen for compounds that inhibit HCV IRES-mediated translation. Treatment with IFN- $\alpha$ , IL-1 $\beta$ , cyclosporin A (CsA) or TGF- $\beta$ , all factors known to repress HCV replication (Blight et al., 2000; Zhu and Liu, 2003; Watashi et al., 2003; Murata et al., 2005), reduced the observed luciferase activity (Fig. 2A), demonstrating the effectiveness of this system. Conversely, the compound PD98059 increased the luciferase activity by 348% compared to vehicle (DMSO)-treated control (Fig. 2A). The increase in luciferase activity induced by PD98059 was not apparent at 6 h after compound addition, but the activity was significantly elevated by 12 h and remained high for at least 3 days (Fig. 2B). Since PD98059 is an inhibitor of the MEK–ERK pathway, we examined its effects on ERK phosphorylation (Fig. 2C). PD98059 treatment blocked ERK phosphorylation, but a clear band of phospho-ERK was seen in DMSO-treated cells due to growth factors present in the growth medium. Luciferase activity increased in a dose-dependent manner following PD98059 treatment (Fig. 2D). Treatment with the inhibitor at 30  $\mu$ M slowed cell growth (Fig. 6B) but did not put cells to death, while >30  $\mu$ M of the chemical resulted in a high degree of toxicity (not shown). We next wished to examine whether PD98059 specifically affected HCV IRES-mediated translation. Using a plasmid based di-cistronic vector




Fig. 1. Constructs used in this study. Schematic representation of the HCV RNA genome (HCV), G418-resistant subgenomic replicon (subgenomic replicon), subgenomic luciferase-replicon (LMH14), mono-cistronic luciferase expression vector with HCV IRES (IRES-luc), mono-cistronic renilla luciferase expression vector with cap and polyA (cap-r-luc-pA) or di-cistronic plasmid-based vector construct. The ORFs are depicted as open boxes.

(Fig. 1 pRLIL-2), we found that PD98059 increased the ratio of IRES-dependent translation to cap-dependent translation (Fig. 3B, 247 and 278% at 30 and 10  $\mu$ M, respectively). Translation downstream of a mono-cistronic mRNA was also enhanced, while cap-dependent translation was not affected (Figs. 3C,D). These results suggest that the positive response of the luciferase-replicon is primarily explained by increased IRES activity. Similar results were obtained when another inhibitor of the MEK–ERK signaling pathway, U0126, was used (Figs. 3E–H).

### *Effect of CGP57380 on HCV IRES*

It has been known that either mitogen-activated protein kinase (MAPK)-interacting protein kinase (MNK) or eukaryotic initiation factor 4E (eIF4E)-binding protein (4EBP) regulates translation initiation downstream of the MEK–ERK pathway (Raught and Gingras, 1999). We first examined the involvement of MNK in the IRES activation using CGP57380, a specific inhibitor of MNK (Knauf et al., 2001). ERK interacts with and phosphorylates MNK in




Fig. 2. Increased luciferase-replicon by PD98059 or U0126. (A) curedMH14 cells transfected with the luciferase-replicon RNA construct (LMH14) were treated with DMSO (0.1%), IFN- $\alpha$  (100 IU/ml), IL-1 $\beta$  (10 ng/ml), cyclosporin A (CsA, 1  $\mu$ g/ml), SB203580 (10  $\mu$ M), dexamethazone (1  $\mu$ M), PD98059 (10  $\mu$ M), BMP-4 (10 ng/ml), TGF- $\beta$  (2 ng/ml), TGF- $\alpha$  (1 ng/ml), cisplatin (1  $\mu$ g/ml) or MMS (methyl methanesulfonate; 0.1 mM). Three days later, cellular luciferase activity was measured. (B) curedMH14 cells transfected with the luciferase-replicon RNA construct were treated with DMSO (white circle), PD98059 (10  $\mu$ M, black box) or IFN- $\alpha$  (100 IU/ml). At the indicated times, cells were harvested for determination of luciferase activity. The activity of DMSO-treated cells was set to 100%. (C) Western blotting analysis of phospho-ERK (upper panel) and total ERK (middle panel) in cells treated with or without PD98059 (10  $\mu$ M) for 10 h. CBB staining pattern of the same blot is used as a loading control (lower panel). (D,E) Dose-dependence of MEK–ERK inhibitors on the activity of the luciferase-replicon. Cells transfected with the luciferase-replicon RNA construct were treated with varying concentrations of PD98059 (D) or U0126 (E), and luciferase activity was subsequently determined. The luciferase activity was shown with the SD value of three independent experiments.

response to growth or stress signals, respectively, and MNK phosphorylates eIF4E (Raught and Gingras, 1999).

Cell treatment with 20  $\mu$ M CGP57380 decreased the luciferase-replicon to 34% (Fig. 4A) and the ratio of IRES-dependent over cap-dependent value to 64% when dicistronic vector (Fig. 4B) was used. There was little to no effect of lower inhibitor concentrations on translation (Figs. 4A,B,C). In order to verify the effectiveness of CGP57380, we examined the activation of eIF4E by blotting with an anti-phospho-eIF4E antibody. Treatment with CGP57380 clearly eliminated eIF4E phosphorylation, and a partial reduction in eIF4E phosphorylation was seen following treatment with PD98059, even though total eIF4E levels were unchanged (Fig. 4D).

These data, combined with accumulating evidence (Scheper and Proud, 2002), suggest that eIF4E phosphorylation does not play a positive role in cap-dependent translation, and, moreover, it may limit cap-dependent

translation in cultured cells, although the physiological significance of eIF4E phosphorylation remains controversial. Nevertheless, drug-induced reduction in eIF4E phosphorylation did not enhance IRES-dependent translation compared to cap-dependent translation.

#### Effect of 4EBP on HCV IRES

An additional key translation regulator downstream of the MEK–ERK pathway is the eIF4E-binding protein 4EBP. When eIF4E is bound by 4EBP, ribosomes are not recruited to the cap structure and translation is blocked. Among the three isoforms, 4EBP1 is the best characterized. The binding of 4EBP1 with eIF4E is controlled by the phosphorylation state of 4EBP1, where the hypo/basal-phosphorylated form of 4EBP1 interacts tightly with eIF4E, but upon hyper-phosphorylation, 4EBP1 binding to eIF4E is inhibited (Gingras et al., 2001). mTOR has been reported to




Fig. 3. Increased HCV IRES by PD98059 or U0126. Dose-dependence of MEK–ERK inhibitors on the activity of the di-cistronic pRLIL-2 vector (A,B,E,F) and mono-cistronic expression vectors (C,D,G,H). (A,E) Cells transfected with di-cistronic pRLIL-2 were incubated with varying concentrations of PD98059 (A) or U0126 (E), and luciferase activity was subsequently determined. IRES-dependent firefly luciferase activity is shown in white, and cap-dependent renilla luciferase activity is in black. (B,F) The results in panels (A) and (E) are shown as the ratio of IRES-dependent over cap-dependent value, respectively. (C,G) Cells transfected with mono-cistronic IRES-luc (white bar) and cap-luc-pA (black bar) were incubated with varying concentrations of PD98059 (C) or U0126 (G), and luciferase activity was subsequently determined. (D,H) The results in panels (C) and (G) are shown as the ratio of IRES-dependent over cap-dependent value, respectively. The luciferase activity was shown with the SD value of three independent experiments.

phosphorylate 4EBP1 (Gingras et al., 1999), and, recently, Herbert et al. (2002) proposed that ERK is involved in the hyper-phosphorylation of 4EBP1.

We investigated a possible role for 4EBP1 in the observed IRES activation by PD98059. Exogenous expression of wild type or dominant active form of 4EBP1 (T46A, Mothe-Satney et al., 2000) elevated the luciferase-replicon to 420 and 325% of control levels, respectively, and PD98059 treatment enhanced these effects (Fig. 5A). A mutant form of 4EBP1 unable to interact with eIF4E (mBD, Mader et al., 1995), however, did not affect the luciferase-replicon activity (Fig. 4A). Luciferase expression driven by a di-cistronic vector resulted in a similar trend (Fig. 5C).

Both the wild type and mBD forms of 4EBP1 were hyper-phosphorylated (Fig. 5D). In the cell line used, Huh-7, endogenous 4EBP1 was not detected (Fig. 5D, vec). The expression levels of wild-type and T46A were reduced compared to mBD, likely as a result of the auto-suppression of cap-dependent translation by the wild type or T46A 4EBP1.

We next tried to eliminate endogenous 4EBP. Knock-down of 4EBP was confirmed following individual siRNA (Fig. 6A) or all siRNAs treatment (Fig. 6B). Among the different 4EBP isoforms, knock-down of 4EBP2 led to the strongest reduction in the luciferase-replicon (Figs. 6C,D) and the IRES/cap-translation in the di-cistronic vector (Figs.




Fig. 4. Effect of CGP57380 on luciferase-replicon or HCV IRES. (A) Cells transfected with the luciferase-replicon RNA construct were treated with CGP57380 (μM). Three days after transfection, cells were harvested for determination of luciferase activity. The activity of DMSO-treated cells was set to 100%. (B) Cells transfected with di-cistronic pRLIL-2 were incubated with CGP57380, and luciferase activity was subsequently determined. IRES-dependent firefly luciferase activity is shown in white, and cap-dependent renilla luciferase activity is in black. (C) The results in panel (B) are shown as the ratio of IRES-dependent over cap-dependent value. The luciferase activity was shown with the SD value of three independent experiments. (D) Western blotting was performed to examine the phosphorylation of eIF4E (upper panel) and total eIF4E (middle panel) in cells treated with or without CGP57380 (20 μM). CBB staining pattern of the same blot is used as a loading control.




Fig. 5. Effect of exogenous expression of 4EBP on luciferase-replicon or HCV IRES. (A) Cells were transfected with the luciferase-replicon RNA construct together with empty vector (vec), vector for 4EBP1, 4EBP1T46A or 4EBP1mBD. 4EBP1T46A is a dominant-active form of 4EBP1, and 4EBP1mBD lacks the ability to bind with eIF4E. Cells were harvested for determination of luciferase activity after 3 days incubation with PD98059 (10  $\mu$ M). White and black bars indicate absence and presence of PD98059, respectively. The data are normalized by cotransfection with the pRL-TK. (B) Cells were cotransfected with dicistronic pRLIL-2 together with empty vector (vec), vector for 4EBP1, 4EBP1T46A or 4EBP1mBD. Luciferase activity was subsequently determined. IRES-dependent firefly luciferase activity is shown in white, and cap-dependent renilla luciferase activity is in black. (C) The results in panel (B) are shown as the ratio of IRES-dependent over cap-dependent value. White and black bars indicate absence and presence of PD98059, respectively. The luciferase activity was shown with the SD value of three independent experiments. (D) Western blotting was performed to examine the expression and phosphorylation state of 4EBP in cells using anti-4EBP antibody. CBB staining pattern of the same blot is used as a loading control.

6G,H). Huh-7 cells express higher levels of 4EBP2 compared to the other isoforms, and we hypothesize that this may account for the observed effect.

The above results suggest that 4EBP proteins, particularly 4EBP2 in this cell line, play an important role in HCV IRES-mediated translation. However, no evidence implicated 4EBP in the ERK-mediated modification of IRES activity because, even in the presence of the mBD mutant or the elimination of 4EBP isoforms, PD98059-mediated activation of IRES-dependent translation still occurred.

#### Effect of PD98059 on G418-resistant subgenomic replicon

Since IRES-mediated translation can regulate RNA replication in cultured HCV replicon cells (He et al., 2003), we tested the effect of PD98059 on G418-resistant replicon RNA replication. When monitored by either real-time RT-PCR (Fig. 7A) or Northern blotting (Fig. 7C), replicon RNA was increased up to 210% of vehicle-treated control by the administration with 30  $\mu$ M of PD98059 for 24 h. The replicon RNA levels decreased at 48 h or later probably because of the cell growth suppression (Fig. 7B). Additionally, PD98059 induced the production of viral protein NS5A (Fig. 7D). Although replicon RNA levels can fluctuate and are not the most stringent test, as Zhu and Liu (2003) also observed, the observed up-regulation of HCV replicon RNA and a viral protein at 24 h strongly suggests an effect of PD98059.

#### PD9805 promotes HCV multiplication in a model of HCV infection

To examine the effects of PD98059 on HCV replication, we infected curedMH14 (Fig. 8A), Huh-7 (B), OUMS-29 H-11 (C) or PH5CH8 (D) cells with HCV-positive serum for 1 day and incubated cells with either PD98059 or vehicle.

curedMH14 had been prepared by curing an HCV replicon cell line of replicon RNA (Murata et al., 2005). OUMS-29/H-11 is a human hepatocyte cell line, in which SV40 large T antigen and hepatocyte nuclear factor 4 (HNF4) had been introduced by stable transfection (Inoue et al., 2001), and PH5CH8 is a human hepatocyte line that had been immortalized with SV40 large T antigen (Ikeda et al., 1998).

HCV replication efficiency is highly dependent on the cell culture conditions, and poor infectivity can lead to little or no replication. However, HCV infectivity was dramatically improved by the addition of 30  $\mu$ M PD98059 (Fig. 8). With 30  $\mu$ M PD98059, virus RNA levels on day 5 were 162, 113 and 146% of the levels of day 1, whereas they were 0, 33 and 0% in curedMH14, OUMS-29 H-11 and PH5CH8 cells treated with DMSO, respectively. Thus, HCV replication was increased by 100-fold or more in curedMH14 and PH5CH8 cells on the fifth day. Huh-7 cells were not as permissive for viral infection under these conditions.

## Discussion

In this study, we found that the addition of PD98059, an inhibitor of the MEK–ERK pathway, enhanced HCV IRES-dependent translation and HCV replication in cultured cells.

Multiple cellular factors bind directly to the HCV IRES including eIF3 (Sizova et al., 1998), the 40S ribosome (Otto et al., 2002), polypyrimidine tract-binding protein (PTB, Ali and Siddiqui, 1995), La autoantigen (Ali and Siddiqui, 1997) and heterogeneous nuclear ribonucleoprotein L (hnRNP L, Hahm et al., 1998). Some of these molecules may play a role in the PD98059-mediated activation of HCV IRES-dependent translation.

Several reports have suggested that translation driven by the HCV IRES (Honda et al., 2000), as well as other IRESes (Pyronnet et al., 2000; Cornelis et al., 2000), is highest in




Fig. 6. Effect of RNAi knock-down of 4EBPs on luciferase-replicon or HCV IRES. (A) Cells were transfected with control siRNA (si cont) or si4EBP1, 2 or 3, independently. Total RNA was collected to examine the levels of relevant 4EBP RNA by RT-PCR. (B) Cells were transfected with control siRNA (si cont) or si4EBP1, 2 and 3, altogether. Total RNA was collected to examine the levels of every isoform of 4EBP RNA by RT-PCR. (C,D) Cells were cotransfected with LMH14 luciferase-replicon RNA construct and various siRNAs, independently (C) or together (D). Luciferase activity was determined after 3 days incubation with or without 10  $\mu$ M PD98059. White and black bars indicate absence and presence of PD98059, respectively. The data are normalized by cotransfection with the pRL-TK. (E,F) Cells were cotransfected with di-cistronic pRLIL-2 together with various siRNAs, independently (E) or together (F). Luciferase activity was subsequently determined. IRES-dependent firefly luciferase activity is shown in white, and cap-dependent renilla luciferase activity is in black. (G,H) The results in panels (E) and (F) are shown as the ratio of IRES-dependent over cap-dependent value. White and black bars indicate absence and presence of PD98059, respectively. The luciferase activity was shown with the SD value of three independent experiments.

the mitotic phase (G2/M) and relatively lower in other phases of the cell cycle. Since the MEK–ERK signaling pathway is largely suppressed in the G2 phase (Tamemoto et al., 1992), MEK–ERK signaling may also be a key regulator of this phenomenon.

In addition to ERK signaling, p38 MAPK and JNK signaling pathways are also involved in translation regulation. Cellular stress negatively affects cap-dependent protein synthesis (Patel et al., 2002), while EMCV (Hirasawa et al., 2003) or *c-myc* (Subkhankulova et al., 2001) IRES-




Fig. 7. Effect of PD98059 on G418-resistant subgenomic replicon. (A) MH14, a G418-resistant subgenomic replicon cell line, was treated with DMSO (white circle), 30  $\mu$ M PD98059 (X), 10  $\mu$ M PD98059 (black box) or 100 IU/ml IFN- $\alpha$  (white triangle) for 1, 3, 5 or 7 days. Following the extraction of total RNA, the quantity of HCV replicon RNA was determined by real-time RT-PCR analysis. (B) In parallel with the experiments in Fig. 5A, cells were treated with DMSO (white circle), 30  $\mu$ M PD98059 (X), 10  $\mu$ M PD98059 (black box) or 100 IU/ml IFN- $\alpha$  (white triangle). Cell numbers were counted at the indicated time points. (C) Total RNA of cells treated for 1 day was also subjected to Northern blot analysis (upper panel). The ethidium bromide staining of ribosomal RNA is shown as an internal control (lower panel). (D) Total protein of cells treated for 1 day was harvested to examine the amount of NS5A (upper panel). CBB staining pattern of the same blot is shown as a loading control (lower panel).

dependent translation is elevated by these signals. Therefore, these signaling pathways may also affect HCV IRES-dependent translation.

A cell culture system supporting HCV replication has not existed for some time. When immortalized hepatocyte cell lines are infected with HCV, viral replication efficiency is not high despite high replication rates in patients. Many researchers have attempted to solve this problem. Ikeda et al. (1998) demonstrated that incubation of cells at lower temperature helps virus replication. Aizaki et al. (2003) used a three-dimensional hepatocyte culturing system. Others varied the bovine serum levels, vitamins, lipids or amino acid composition or the pH of the culture medium. We observed that freshly thawed cells with lower viability supported replication better than rapidly growing cells. We now propose a simple infection system that supports highly efficient HCV replication in cultured cells by adding PD98059 in the medium.

Cells isolated from human liver are cultured in conditions that substantially differ from the in vivo

environment and are often immortalized by oncogene expression. Consequently, many signaling pathways are likely aberrantly regulated in vitro. Among these pathways, it seems likely that ERK signaling is responsible for regulating HCV replication in cultured cells, and PD98059 may help mimic the in vivo environment and facilitate HCV replication by enhancing IRES-dependent translation.

Although treatment with PD98059 increased the replication of viral RNA in various cell lines when infected with HCV-positive serum (Fig. 8), replicon RNA levels were not increased under similar conditions (Fig. 7). The RNA copy number may explain these differences. PD98059 may not enhance the replication of replicon RNA because, in these systems, viral RNA and proteins are abundant even in the absence of the inhibitor. In cells infected with patient serum, highly efficient IRES-dependent translation may be essential for viral replication due to the low copy number of viral RNA per cell.

Mutations of serine residues within NS5A that affect the protein hyper-phosphorylation enhance replication of the virus replicon (Blight et al., 2000), and inhibitors of NS5A kinase(s) activate replication (Neddermann et al., 2004). Since the CMGC group of serine–threonine kinases has been implicated in the phosphorylation of NS5A (Reed et al., 1997), PD98059 might affect the




Fig. 8. Increased HCV multiplication by PD9805 in cells infected with HCV-positive serum. curedMH14 (A), Huh-7 (B), OUMS-29 H-11 (C) or PH5CH8 (D) cells were infected or mock-infected (white triangle) with HCV-positive serum for 1 day. After extensive washing with PBS, the cells were cultured with fresh medium supplemented with DMSO (white circle), 30  $\mu$ M PD98059 (X), 10  $\mu$ M PD98059 (black box). At the indicated times, total RNA was extracted, and the quantity of HCV RNA was determined by real-time RT-PCR analysis.

phosphorylation of the NS5A protein and thereby elevate replication. When we treated cells with PD98059, however, the levels of hyper-phosphorylated NS5A were not affected (not shown). This suggests that PD98059 activates viral replication through the enhancement of IRES-mediated translation but not through a reduction in phosphorylation state of NS5A.

Multiplication of influenza virus (Pleschka et al., 2001), borna disease virus (Planz et al., 2001), coxsackievirus (Luo et al., 2002), visna virus (Barber et al., 2002), human immunodeficiency virus (Montes et al., 2000), vaccinia virus (de Magalhaes et al., 2001), Epstein–Barr virus (Gao et al., 2001), cytomegalovirus (Rodems and Spector, 1998) and human herpesvirus-8 (Akula et al., 2004) are promoted by MEK–ERK signaling pathway activation. Activation of this pathway results in efficient cell cycle promotion, high cellular or viral gene production and increased availability of biomaterials, such as nucleotides or amino acids. Many of these viruses, therefore, likely exploit the cellular environment created through the activation of the MEK–ERK pathway. Interestingly, replication of the hepatitis B virus (HBV) is negatively regulated by the MAPK signaling pathway (Zheng et al., 2003). Because both HBV and HCV infect the same target organ, it is possible that both viruses have evolved similar means to exploit host signaling pathways. Much research is needed to identify the factors conferring organ specificity to HCV, however.

## Materials and methods

### *Cell culture, antibodies and reagents*

Huh-7 or curedMH14 cells (Murata et al., 2005) were maintained in Dulbecco's modified Eagle medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 units/ml nonessential amino acids (Invitrogen, Carlsbad, CA) and 100 µg/ml penicillin and streptomycin sulfate (Invitrogen, Carlsbad, CA). MH14 replicon cells (Miyanari et al., 2003) were cultured in the same medium with 300 µg/ml G418 (Geneticin, Invitrogen, Carlsbad, CA). OUMS-29/H-11 cells (Inoue et al., 2001, Fukaya et al., 2001) were maintained in ASF-104 medium (Ajinomoto, Tokyo, Japan) with 100 µg/ml penicillin and streptomycin sulfate (Invitrogen, Carlsbad, CA), and PH5CH8 cells were cultured as described (Ikeda et al., 1998).

Rabbit anti-ERK, rabbit anti-phospho-ERK, rabbit anti-eIF4E and mouse anti-phospho-eIF4E antibodies were purchased from Cell Signaling Technology (Beverly, MA). Rabbit anti-4EBP antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). Horseshoe-peroxidase-linked goat antibodies to mouse or rabbit IgG were from Amersham Biosciences (Piscataway, NJ). PD98059 and other inhibitors were obtained commercially from Calbiochem-Novabiochem (San Diego, CA).

### *Plasmid construction*

The pLMH14, used to synthesize the luciferase-replicon LMH14 RNA and mono-cistronic IRES-luc RNA, has been described previously (Murata et al., 2005). The di-cistronic plasmid vector, pRLIL-2, was based on the pRL-CMV Vector (Promega, Madison, WI) and contains HCV IRES sequence (complete 5'-UTR sequence and initial part of the Core gene) plus the firefly luciferase sequence obtained from pGL2 Vector (Promega, Madison, WI).

The human 4EBP1 gene was cloned by RT-PCR into the mammalian expression vector pcDNA3 (Invitrogen, Carlsbad, CA) to obtain pcDNA4EBP. Primers used to clone the gene were 5'-cggaaatcgatgtccggggcagcagctgc-3' and 5'-ctgactcgagttaaagtccatctcaactgtg-3'. To generate pcDNS4EBPT46A and pcDNA4EBPmBD plasmids, mutations were inserted into pcDNA4EBP by PCR-based site-directed mutagenesis using the primers 5'-ctggtacc-tcccggggcgggtgctgaagagcgtg-3' for T46A and 5'-gaggtac-caggatcatctatgaccggaattcgcggcggagtgtcggaaactc-3' for mBD. Bold letters in the primers denote the substituted nucleotides.

### *RNA synthesis in vitro*

In order to synthesize the LMH14 luciferase-replicon RNA or mono-cistronic IRES-luc RNA, pLMH14 was digested with *Xba*I or *Kpn*I, respectively, and subjected to in vitro transcription using a MEGAscript T7 kit (Ambion, Austin, TX) according to the manufacturer's instructions. Following DNase treatment, RNA was purified by lithium chloride precipitation. For production of mono-cistronic cap-rIuc-pA RNA, the pRL-TK Vector (Promega, Madison, WI) was cut with *Xba*I and transcribed in vitro using mMACHINE T7 Kit (Ambion, Austin, TX) for capping. Poly(A) Tailing Kit (Ambion, Austin, TX) was then used for polyadenylation of the RNA.

### *Luciferase assay*

Lipofection with RNA was performed using DMRIE-C reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Plasmid DNA, including pRLIL-2, was transfected into cells using FuGENE6 reagent (Roche, Indianapolis, IN). Luciferase activity was measured using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI). Assays were performed in triplicate; standard deviations are denoted by bars in the figures.

### *Real-time RT-PCR analysis*

Total RNA was extracted from cells using Sepasol RNAI super reagent (Nacalai Tesque, Kyoto, Japan) according to the manufacturer's protocol. The 5'-UTR of HCV genomic RNA was quantified with the ABI PRISM 7700 sequence detector (Applied Biosystems, Foster City,



CA) as described (Watashi et al., 2003) using the 5'-CGGGAGAGCCATAGTGG-3' (forward) and 5'-AGTAC-CACAAGGCCTTTTCG-3' (reverse) primers and the fluorescent probe 5'-CTGCGGAACCGGTGAGTACAC-3'. As an internal control, ribosomal RNA was quantified using TaqMan ribosomal RNA control reagents (Applied Biosystems, Foster City, CA).

#### Northern and Western blot analysis

Total RNA was extracted from cells using Sepasol RNAi super reagent (Nacalai Tesque, Kyoto, Japan). Northern or Western blot analysis was performed as described previously (Kishine et al., 2002). The 1.5-kb *EcoRI* fragment of pNNRZ2 was used as the probe, which corresponds to the C-terminal half of the NS5A gene and N-terminal half of the NS5B gene.

#### In vitro HCV infection

The in vitro HCV infection experiment was carried out as described previously (Watashi et al., 2003). In short, cells were infected with the serum which was prepared from an HCV-positive blood donor. At 24 h post-inoculation, the cells were washed three times with PBS and maintained with fresh medium with DMSO or PD98059 until the extraction of the RNA sample.

#### siRNA

Sequences of siRNAs (Invitrogen, Carlsbad, CA) were as follows: 5'-aactcactgtgacaaaaca-3' for 4EBP1, 5'-aagactcacaagtagaagtaa-3' for 4EBP2 and 5'-aagctggagtgcagaactca-3' for 4EBP3. Before using, the siRNAs were dissolved in RNase-free water, denatured once at 98 °C for 1 min and annealed at 37 °C for 1 h. For electroporation of siRNA,  $4 \times 10^5$  cells and 0.8 µg siRNA were suspended in 400 µl of OPTI-MEM (Invitrogen, Carlsbad, CA) and pulsed at 250 V and 950 µF using GenePulser (Bio Rad, Hercules, CA) at 4 °C. To evaluate the silencing effects of siRNAs, RT-PCR was performed using One-Step RT-PCR Kit (TaKaRa, Ohtsu, Japan) according to the manufacturer's instruction. Primer sequences used were as follows: 4EBP1, 5'-cggaaattcgatgtccggggcagcagctgc-3' and 5'-ctgactcgagttaaatgtccatctcaactgtg-3', 4EBP2, 5'-cggaaattcatgtctctgcagccggcag-3' and 5'-ctgactcgagtcagatgtccatctcgaac-3', 4EBP3, 5'-cggaaattcatgcaactccactagctg-3' and 5'-ctgactcgagttagatgtccattcaaatg-3', GAPDH, 5'-tttctcgagatggggaaggtgaagctg-3' and 5'-ccggaattctggaggatctcgtctg-3'.

#### Acknowledgments

We wish to thank Dr. Gram (Novartis Pharma, Basel) for providing CGP57380. This work was supported by grants-in-aid for cancer research and by the second-term compre-

hensive 10-year strategy for cancer control and by the Ministry of Health, Labor, and Welfare, as well as grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology, grants-in-aid by the Japanese Society for the Promotion of Science (JSPS) and by the Program for Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research (OPSR) of Japan. T.M. is a recipient of a JSPS Postdoctoral Fellowship.

#### References

- Aizaki, H., Nagamori, S., Matsuda, M., Kawakami, H., Hashimoto, O., Ishiko, H., Kawada, M., Matsuura, T., Hasumura, S., Matsuura, Y., Suzuki, T., Miyamura, T., 2003. Production and release of infectious hepatitis C virus from human liver cell cultures in the three-dimensional radial-flow bioreactor. *Virology* 314 (1), 16–25.
- Akula, S.M., Ford, P.W., Whitman, A.G., Hamden, K.E., Shelton, J.G., McCubrey, J.A., 2004. Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. *Oncogene* 23 (30), 5227–5241.
- Ali, N., Siddiqui, A., 1995. Interaction of polypyrimidine tract-binding protein with the 5' noncoding region of the hepatitis C virus RNA genome and its functional requirement in internal initiation of translation. *J. Virol.* 69 (10), 6367–6375.
- Ali, N., Siddiqui, A., 1997. The La antigen binds 5' noncoding region of the hepatitis C virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry site-mediated translation. *Proc. Natl. Acad. Sci. U.S.A.* 94 (6), 2249–2254.
- Barber, S.A., Bruett, L., Douglass, B.R., Herbst, D.S., Zink, M.C., Clements, J.E., 2002. Visna virus-induced activation of MAPK is required for virus replication and correlates with virus-induced neuropathology. *J. Virol.* 76 (2), 817–828.
- Blight, K.J., Kolykhalov, A.A., Rice, C.M., 2000. Efficient initiation of HCV RNA replication in cell culture. *Science* 290 (5498), 1972–1974.
- Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 244, 359–362.
- Cornelis, S., Bruynooghe, Y., Denecker, G., Van Huffel, S., Tinton, S., Beyaert, R., 2000. Identification and characterization of a novel cell cycle-regulated internal ribosome entry site. *Mol. Cell* 5 (4), 597–605.
- de Magalhães, J.C., Andrade, A.A., Silva, P.N., Sousa, L.P., Ropert, C., Ferreira, P.C., Kroon, E.G., Gazzinelli, R.T., Bonjardim, C.A., 2001. A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication. *J. Biol. Chem.* 276 (42), 38353–38360.
- Forton, D.M., Karayiannis, P., Mahmud, N., Taylor-Robinson, S.D., Thomas, H.C., 2004. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. *J. Virol.* 78 (10), 5170–5183.
- Fukaya, K., Asahi, S., Nagamori, S., Sakaguchi, M., Gao, C., Miyazaki, M., Namba, M., 2001. Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1 and 1A2 activities from fetal liver tissue by transfection of SV40 LT. *In Vitro Cell. Dev. Biol.: Anim.* 37 (5), 266–269.
- Gao, X., Ikuta, K., Tajima, M., Sairenji, T., 2001. 12-*O*-tetradecanoylphorbol-13-acetate induces Epstein–Barr virus reactivation via NF-κB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase. *Virology* 286 (1), 91–99.
- Gingras, A.C., Gygi, S.P., Raught, B., Polakiewicz, R.D., Abraham, R.T., Hoekstra, M.F., Aebersold, R., Sonenberg, N., 1999. Regulation of 4EBP1 phosphorylation: a novel two-step mechanism. *Genes Dev.* 13 (11), 1422–1437.
- Gingras, A.C., Raught, B., Gygi, S.P., Niedzwiecka, A., Miron, M., Burley,

- S.K., Polakiewicz, R.D., Wyslouch-Cieszynska, A., Aebersold, R., Sonenberg, N., 2001. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. *Genes Dev.* 15 (21), 2852–2864.
- Goodman, Z.D., Ishak, K.G., 1995. Histology of hepatitis C virus infection. *Semin. Liver. Dis.* 15, 70–81.
- Hahn, B., Kim, Y.K., Kim, J.H., Kim, T.Y., Jang, S.K., 1998. Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus. *J. Virol.* 72 (11), 8782–8788.
- He, Y., Yan, W., Coito, C., Li, Y., Gale Jr., M., Katze, M.G., 2003. The regulation of hepatitis C virus (HCV) internal ribosome-entry site-mediated translation by HCV replicons and nonstructural proteins. *J. Gen. Virol.* 84 (Pt. 3), 535–543.
- Herbert, T.P., Tee, A.R., Proud, C.G., 2002. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. *J. Biol. Chem.* 277 (13), 11591–11596.
- Hirasawa, K., Kim, A., Han, H.S., Han, J., Jun, H.S., Yoon, J.W., 2003. Effect of p38 mitogen-activated protein kinase on the replication of encephalomyocarditis virus. *J. Virol.* 77 (10), 5649–5656.
- Honda, M., Ping, L.H., Rijnbrand, R.C., Amphlett, E., Clarke, B., Rowlands, D., Lemon, S.M., 1996. Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. *Virology* 222 (1), 31–42.
- Honda, M., Kaneko, S., Matsushita, E., Kobayashi, K., Abell, G.A., Lemon, S.M., 2000. Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. *Gastroenterology* 118 (1), 152–162.
- Ikeda, M., Sugiyama, K., Mizutani, T., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K., Kato, N., 1998. Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. *Virus Res.* 56 (2), 157–167.
- Inoue, Y., Miyazaki, M., Tsuji, T., Sakaguchi, M., Fukaya, K., Huh, N.H., Namba, M., 2001. Reactivation of liver-specific gene expression in an immortalized human hepatocyte cell line by introduction of the human HNF4alpha2 gene. *Int. J. Mol. Med.* 8 (5), 481–487.
- Kishine, H., Sugiyama, K., Hijikata, M., Kato, N., Takahashi, H., Noshi, T., Nio, Y., Hosaka, M., Miyanari, Y., Shimotohno, K., 2002. Subgenomic replicon derived from a cell line infected with the hepatitis C virus. *Biochem. Biophys. Res. Commun.* 293 (3), 993–999.
- Knauf, U., Tschoop, C., Gram, H., 2001. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. *Mol. Cell. Biol.* 21 (16), 5500–5511.
- Laporte, J., Bain, C., Maurel, P., Inchauspe, G., Agut, H., Cahour, A., 2003. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. *Blood* 101 (1), 52–57.
- Lerat, H., Shimizu, Y.K., Lemon, S.M., 2000. Cell type-specific enhancement of hepatitis C virus internal ribosome entry site-directed translation due to 5' nontranslated region substitutions selected during passage of virus in lymphoblastoid cells. *J. Virol.* 74 (15), 7024–7031.
- Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R., 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285 (5424), 110–113.
- Lott, W.B., Takyar, S.S., Tuppen, J., Crawford, D.H., Harrison, M., Sloots, T.P., Gowans, E.J., 2001. Vitamin B12 and hepatitis C: molecular biology and human pathology. *Proc. Natl. Acad. Sci. U.S.A.* 98 (9), 4916–4921.
- Luo, H., Yanagawa, B., Zhang, J., Luo, Z., Zhang, M., Esfandiari, M., Carthy, C., Wilson, J.E., Yang, D., McManus, B.M., 2002. Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. *J. Virol.* 76 (7), 3365–3373.
- Mader, S., Lee, H., Pause, A., Sonenberg, N., 1995. The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. *Mol. Cell. Biol.* 15 (9), 4990–4997.
- Miyanari, Y., Hijikata, M., Yamaji, M., Hosaka, M., Takahashi, H., Shimotohno, K., 2003. Hepatitis C virus non-structural proteins in the probable membranous compartment function in viral genome replication. *J. Biol. Chem.* 278 (50), 50301–50308.
- Montes, M., Tagieva, N.E., Heveker, N., Nahmias, C., Baleux, F., Trautmann, A., 2000. SDF-1-induced activation of ERK enhances HIV-1 expression. *Eur. Cytokine Network* 11 (3), 470–477.
- Mothe-Satney, I., Yang, D., Fadden, P., Haystead, T.A., Lawrence Jr., J.C., 2000. Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. *Mol. Cell. Biol.* 20 (10), 3558–3567.
- Murata, T., Ohshima, T., Yamaji, M., Hosaka, M., Miyanari, Y., Hijikata, M., Shimotohno, K., 2005. Suppression of hepatitis C virus replicon by TGF-beta. *Virology* 331 (2), 407–417.
- Murphy, F.A., Fauquet, C.M., Bishop, D.H.L., Ghabrial, S.A., Jarvis, A.W., Martelli, G.P., Mayo, M.A., Summers, M.D., 1995. Classification and Nomenclature of Viruses: Sixth Report of the International Committee on Taxonomy of Viruses. Springer-Verlag, Vienna, Austria, pp. 424–426.
- Neddermann, P., Quintavalle, M., Di Pietro, C., Clementi, A., Cerretani, M., Altamura, S., Bartholomew, L., De Francesco, R., 2004. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. *J. Virol.* 78 (23), 13306–13314.
- Otto, G.A., Lukavsky, P.J., Lancaster, A.M., Sarnow, P., Puglisi, J.D., 2002. Ribosomal proteins mediate the hepatitis C virus IRES-HeLa 40S interaction. *RNA* 8 (7), 913–923.
- Patel, J., McLeod, L.E., Vries, R.G., Flynn, A., Wang, X., Proud, C.G., 2002. Cellular stresses profoundly inhibit protein synthesis and modulate the states of phosphorylation of multiple translation factors. *Eur. J. Biochem.* 269 (12), 3076–3085.
- Planz, O., Pleschka, S., Ludwig, S., 2001. MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells. *J. Virol.* 75 (10), 4871–4877.
- Pleschka, S., Wolff, T., Ehrhardt, C., Hobom, G., Planz, O., Rapp, U.R., Ludwig, S., 2001. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. *Nat. Cell Biol.* 3 (3), 301–305.
- Pyronnet, S., Pradayrol, L., Sonenberg, N., 2000. A cell cycle-dependent internal ribosome entry site. *Mol. Cell* 5 (4), 607–616.
- Raught, B., Gingras, A.C., 1999. eIF4E activity is regulated at multiple levels. *Int. J. Biochem. Cell Biol.* 31 (1), 43–57.
- Reed, K.E., Xu, J., Rice, C.M., 1997. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase. *J. Virol.* 71 (10), 7187–7197.
- Robinson, M.J., Cobb, M.H., 1997. Mitogen-activated protein kinase pathways. *Curr. Opin. Cell Biol.* 9 (2), 180–186.
- Rodems, S.M., Spector, D.H., 1998. Extracellular signal-regulated kinase activity is sustained early during human cytomegalovirus infection. *J. Virol.* 72 (11), 9173–9180.
- Scheper, G.C., Proud, C.G., 2002. Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? *Eur. J. Biochem.* 269 (22), 5350–5359.
- Sizova, D.V., Kolupaeva, V.G., Pestova, T.V., Shatsky, I.N., Hellen, C.U., 1998. Specific interaction of eukaryotic translation initiation factor 3 with the 5' nontranslated regions of hepatitis C virus and classical swine fever virus RNAs. *J. Virol.* 72 (6), 4775–4782.
- Subkhankulova, T., Mitchell, S.A., Willis, A.E., 2001. Internal ribosome entry segment-mediated initiation of c-Myc protein synthesis following genotoxic stress. *Biochem. J.* 359 (Pt. 1), 183–192.
- Takahashi, H., Yamaji, M., Hosaka, M., Kishine, H., Hijikata, M., Shimotohno, K., 2005. Analysis of the 5' end structure of HCV subgenomic RNA replication in an Huh7 cell line. *Intervirology* 48 (2–3), 104–111.
- Tamemoto, H., Kadowaki, T., Tobe, K., Ueki, K., Izumi, T., Chatani, Y., Kohno, M., Kasuga, M., Yazaki, Y., Akanuma, Y., 1992. Biphasic activation of two mitogen-activated protein kinases during the cell cycle in mammalian cells. *J. Biol. Chem.* 267 (28), 20293–20297.

- Tsukiyama-Kohara, K., Iizuka, N., Kohara, M., Nomoto, A., 1992. Internal ribosome entry site within hepatitis C virus RNA. *J. Virol.* 66 (3), 1476–1483.
- Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., Shimotohno, K., 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. *Hepatology* 38 (5), 1282–1288.
- Zheng, Y., Li, J., Johnson, D.L., Ou, J.H., 2003. Regulation of hepatitis B virus replication by the ras-mitogen-activated protein kinase signaling pathway. *J. Virol.* 77 (14), 7707–7712.
- Zhu, H., Liu, C., 2003. Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. *J. Virol.* 77 (9), 5493–5498.